ClinicalTrials.gg
RecruitingNCT07475728EMS BUPUpdated Aug 27, 2026

EMS-Initiated Buprenorphine

An observational study in Opioid Use Disorder, sponsored by Yale University. Recruiting at 3 sites in United States. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Yale University · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
495
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Opioid-Related Disorders by Yale University — 20 open to participants now, 24 under way, 1 of them phase 3. Opioid-Related Disorders · Yale University.

Planned enrollment
Largest of 11
495 · median 108
Started
2026
with 7 others
Observational
11 of 106
4 open now
Primary completion
2029-03
later than 20 of 23 live
Registered
101st of 106
by date

Among the 106 studies in Opioid-Related Disorders by Yale University, this one has the largest planned enrollment of the 11 observational ones that give a count, is one of 8 that started in 2026, is one of 11 observational ones, reaches primary completion later than 20 of the 23 other live ones, and was the 101st registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

20 of the 106 studies in Opioid-Related Disorders by Yale University are open now, in 4 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Opioid-Related Disorders by Yale University, or all of them as a file.
02

Study summary

This is a multisite EMS study that will first conduct a sequence of pragmatic, prehospital field studies to provide preliminary feasibility, acceptability, and safety data for refinement and enhancement of a subsequent single-arm prospective trial that will provide preliminary effectiveness data, from which to build a larger randomized control trail (RCT) trial.

Read the detailed description

Evaluating the EMS clinical protocol details and subsequent research procedures will be accomplished by enrolling approximately five EMS-initiated BUP encounters per site. Subsequently, a pragmatic field study will engage approximately thirty successful BUP initiations to assess the feasibility, acceptability, and safety of the EMS clinical protocol and follow up procedures. Investigators will also enroll a cohort of up to thirty patients per site who are eligible for BUP but refuse for informative purposes only, to understand reasons for refusal. Qualitative data on the refusal cohort will be analyzed separately. The outcomes of the pragmatic studies will inform revisions to the EMS clinical protocol.

A single-arm prospective trial of approximately 100 patients per site will subsequently be conducted to collect preliminary data on the effectiveness of EMS-initiated BUP on engagement in MOUD treatment within 10 and 30 days after the EMS-initiated BUP encounter.

03

Conditions studied

  • Opioid Use Disorder

Keywords

  • Emergency Medical Services
  • Buprenorphine
  • Substance use disorder treatment
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals in the prehospital setting with OUD 1) presenting with overdose requiring naloxone reversal or 2) in acute opioid abstinence withdrawal offered an EMS clinical protocol across approximately three ED-EMS systems.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • Treated by the EMS-Initiated buprenorphine clinical protocol which includes:

Patients that accept EMS-Initiated BUP protocol. Patients offered the EMS-Initiated BUP protocol but declined.1

  • Willing to follow study procedures.
  • Able to speak English sufficiently to understand study procedures, and to provide verbal and electronic/written consent.

Exclusion criteria

Exclusion Criteria:

  • Patients who lack decision making capacity
  • Patients who are in police or protective custody
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
495 participants (estimated)
Patient registry
No

Groups and cohorts

  • Participants

    Individuals with opioid use disorder (OUD) who encounter Emergency Medical Services (EMS) in the prehospital setting under one of two circumstances: (1) They have experienced an overdose requiring naloxone reversal or (2) They are in acute opioid abstinence withdrawal and are offered an EMS-initiated BUP clinical protocol.

06

What researchers measure

Primary outcomes

  1. Primary Outcome Measure for Pragmatic Field Study

    Feasibility and acceptability will be measured by the proportion of patients who accept EMS-initiated BUP among all patients who are offered the EMS-initiated BUP clinical protocol.

    Time frame: Baseline

  2. Primary Outcome Measure for the Single Arm Prospective Trial

    The proportion of participants engaged in MOUD within 10 days post EMS-initiated BUP among participants who received BUP and consented to be followed

    Time frame: Within 10 days after EMS encounter

Secondary outcomes

  1. Engagement in Treatment (30)

    The proportion of patients participating in MOUD treatment

    Time frame: Within 30 days after EMS encounter

  2. Precipitated Withdrawal

    The proportion of patients who develop precipitated withdrawal among all those who accepted EMS buprenorphine.

    Time frame: Baseline

  3. ED Visits and Hospitalizations

    Proportion of patients with subsequent ED visits and hospitalizations post EMS BUP among those who accepted EMS buprenorphine

    Time frame: Within 30 days after EMS encounter

  4. Adverse Events

    The number of adverse events per participant after EMS-BUP initiation among all those who accepted EMS-BUP

    Time frame: Within 30 days after EMS-BUP encounter

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — In line with the National Institutes of Health Helping to End Addiction Long-term (NIH HEAL) Initiative Public Access and Data Sharing Policy, publications and underlying primary data will be made available to the public.

Time frame: Data will be made available after 1) The primary outcome paper has been accepted for publication, or 2) the data is locked for more than 18 months, whichever comes first.

Access criteria: De-identified scientific data generated from this study will be made available to the public in the NIDA data repository, per NIDA CTN policy and the Data Management and Sharing Plan for the study.

Data sharing details ↗ · datashare.nida.nih.gov

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Mar 2029, 34 months after the start.

Of 74 non-industry observational studies under Opioid-Related Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 34 months is above that.

Counting every sponsor, half of 88 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2026
First posted
Mar 16, 2026
StartActual
May 21, 2026
Primary completionEst.
Mar 2029
CompletionEst.
May 2029
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07475728
Lead sponsor
Yale University
Collaborators
National Drug Abuse Treatment Clinical Trials Network, The Emmes Company, LLC, National Institute on Drug Abuse (NIDA)
Responsible party
Sponsor
First posted
Mar 16, 2026
Start date
May 21, 2026
Primary completion
Mar 2029 (estimated)
Completion
May 2029 (estimated)
Last update
Aug 27, 2026

Study contacts

Gail D'Onofrio, MD, MS
Contact
gail.donofrio@yale.edu
12037857059
Gerard Carroll, MD
Contact
Carroll-Gerard@CooperHealth.edu
Gail D'Onofrio, MD, MS
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion